|Bid||0.00 x 900|
|Ask||0.00 x 800|
|Day's range||24.65 - 27.78|
|52-week range||16.85 - 45.04|
|Beta (5Y monthly)||0.89|
|PE ratio (TTM)||N/A|
|Earnings date||26 Feb 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||50.92|
Apellis Pharmaceuticals' (APLS) experimental drug pegcetacoplan outperformed Alexion's blockbuster medicine, Soliris, in a phase III head-to-head study. Shares soar.
Investors need to pay close attention to Apellis Pharmaceuticals (APLS) stock based on the movements in the options market lately.
If you want to compound wealth in the stock market, you can do so by buying an index fund. But one can do better than...